[1]
|
Davatchi, F., et al. (2017) Behcet’s Disease: Epidemiology, Clinical Manifestations, and Diagnosis. Expert Review of Clinical Immunology, 13, 57-65. https://doi.org/10.1080/1744666X.2016.1205486
|
[2]
|
Boehncke, W.H. and Schön, M.P. (2015) Psoriasis. The Lancet, 386, 983-994.
https://doi.org/10.1016/S0140-6736(14)61909-7
|
[3]
|
Kaufman, B.P. and Alexis, A.F. (2018) Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. American Journal of Clinical Dermatology, 19, 405-423. https://doi.org/10.1007/s40257-017-0332-7
|
[4]
|
Yamamoto, T., et al. (2016) Epidemiological Analysis of Psoriatic Arthritis Patients in Japan. The Journal of Dermatology, 43, 1193-1196. https://doi.org/10.1111/1346-8138.13342
|
[5]
|
Stuart, P.E., et al. (2015) Genome-Wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. The American Journal of Human Genetics, 97, 816-836.
https://doi.org/10.1016/j.ajhg.2015.10.019
|
[6]
|
Yazici, H., et al. (2018) Behçet Syndrome: A Contemporary View. Nature Reviews Rheumatology, 14, 107-119.
https://doi.org/10.1038/nrrheum.2017.208
|
[7]
|
Gül, A. (2015) Pathogenesis of Behçet’s Disease: Autoinflamma-tory Features and Beyond. Seminars in Immunopathology, 37, 413-418. https://doi.org/10.1007/s00281-015-0502-8
|
[8]
|
中华医学会风湿病学分会. 白塞病诊断和治疗指南[J]. 中华风湿病学杂志, 2011, 15(5): 345-347.
|
[9]
|
Griffiths, C.E. and Barker, J.N. (2007) Pathogenesis and Clinical Features of Psoriasis. The Lancet, 370, 263-271.
https://doi.org/10.1016/S0140-6736(07)61128-3
|
[10]
|
Gudjonsson, J.E. and Elder, J.T. (2007) Psoriasis: Epidemi-ology. Clinics in Dermatology, 25, 535-546.
https://doi.org/10.1016/j.clindermatol.2007.08.007
|
[11]
|
Asahina, A., et al. (2016) Serum C-Reactive Protein Levels in Japanese Patients with Psoriasis and Psoriatic Arthritis: Long-Term Differential Effects of Biologics. The Journal of Dermatology, 43, 779-784.
https://doi.org/10.1111/1346-8138.13213
|
[12]
|
Takata, T., et al. (2016) Detection of Asymptomatic Enthesitis in Psoriasis Patients: An Onset of Psoriatic Arthritis? The Journal of Dermatology, 43, 650-654. https://doi.org/10.1111/1346-8138.13212
|
[13]
|
Gisondi, P., et al. (2018) Psoriasis and the Metabolic Syndrome. Clinics in Dermatology, 36, 21-28.
https://doi.org/10.1016/j.clindermatol.2017.09.005
|
[14]
|
Hu, S.C. and Lan, C.E. (2017) Psoriasis and Cardiovascu-lar Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. In-ternational Journal of Molecular Sciences, 18, 2211.
https://doi.org/10.3390/ijms18102211
|
[15]
|
Diani, M., et al. (2019) Increased Frequency of Activated CD8(+) T Cell Effectors in Patients with Psoriatic Arthritis. Scientific Reports, 9, Article No. 10870. https://doi.org/10.1038/s41598-019-47310-5
|
[16]
|
Pineton, D.C.M., et al. (2012) New Insights into the Pathogene-sis of Behçet’s Disease. Autoimmunity Reviews, 11, 687-698. https://doi.org/10.1016/j.autrev.2011.11.026
|
[17]
|
Mahmoudi, M., et al. (2018) Epistatic Interaction of ERAP1 and HLA-B*51 in Iranian Patients with Behçet’s Disease. Scientific Reports, 8, Article No. 17612. https://doi.org/10.1038/s41598-018-35700-0
|
[18]
|
Nograles, K.E., Davidovici, B. and Krueger, J.G. (2010) New Insights in the Immunologic Basis of Psoriasis. Seminars in Cutaneous Medicine and Surgery, 29, 3-9. https://doi.org/10.1016/j.sder.2010.03.001
|
[19]
|
Kim, J., et al. (2010) Imbalance of Th17 to Th1 Cells in Behçet’s Disease. Clinical and Experimental Rheumatology, 28, S16-S19.
|
[20]
|
Hahn, H.J., et al. (2021) Association of Behçet Disease with Psoriasis and Psoriatic Arthritis. Scientific Reports, 11, Article No. 2531. https://doi.org/10.1038/s41598-021-81972-4
|
[21]
|
Hahn, H.J., et al. (2019) A Nationwide, Population-Based Co-hort Study on Potential Autoimmune Association of Ménière Disease to Atopy and Vitiligo. Scientific Reports, 9, Article No. 4406.
https://doi.org/10.1038/s41598-019-40658-8
|
[22]
|
Cañete, J.D., et al. (2009) Distinct Synovial Immunopathology in Behçet Disease and Psoriatic Arthritis. Arthritis Research & Therapy, 11, R17. https://doi.org/10.1186/ar2608
|
[23]
|
Direskeneli, H., et al. (2008) Thalidomide Has Both Anti-Inflammatory and Regulatory Effects in Behcet’s Disease. Clinical Rheumatology, 27, 373-375. https://doi.org/10.1007/s10067-007-0786-8
|
[24]
|
Cho, S., et al. (2013) Behçet’s Disease in Concurrence with Pso-riasis. The Journal of the European Academy of Dermatology and Venereology, 27, e113-e118. https://doi.org/10.1111/j.1468-3083.2012.04559.x
|
[25]
|
Aktulga, E., et al. (1980) A Double Blind Study of Colchi-cine in Behçet’s Disease. Haematologica, 65, 399-402.
|
[26]
|
Hatemi, G., et al. (2018) 2018 Update of the EULAR Recommendations for the Management of Behçet’s Syndrome. Annals of the Rheumatic Diseases, 77, 808-818. https://doi.org/10.1136/annrheumdis-2018-213225
|
[27]
|
Leccese, P., et al. (2019) Management of Skin, Mucosa and Joint Involvement of Behçet’s Syndrome: A Systematic Review for Update of the EULAR Recommendations for the Management of Behçet’s Syndrome. Seminars in Arthritis and Rheumatism, 48, 752-762. https://doi.org/10.1016/j.semarthrit.2018.05.008
|
[28]
|
Gooderham, M. and Papp, K. (2015) Selective Phos-phodiesterase Inhibitors for Psoriasis: Focus on Apremilast. BioDrugs, 29, 327-339. https://doi.org/10.1007/s40259-015-0144-3
|
[29]
|
Schafer, P. (2012) Apremilast Mechanism of Action and Applica-tion to Psoriasis and Psoriatic Arthritis. Biochemical Pharmacology, 83, 1583-1590. https://doi.org/10.1016/j.bcp.2012.01.001
|
[30]
|
Bäumer, W., et al. (2007) Highly Selective Phosphodiesterase 4 In-hibitors for the Treatment of Allergic Skin Diseases and Psoriasis. Inflammation & Allergy—Drug Targets, 6, 17-26. https://doi.org/10.2174/187152807780077318
|
[31]
|
Hatemi, G., et al. (2015) Apremilast for Behçet’s Syn-drome—A Phase 2, Placebo-Controlled Study. The New England Journal of Medicine, 372, 1510-1518. https://doi.org/10.1056/NEJMoa1408684
|